Correction to: Nature Communications https://doi.org/10.1038/s41467-023-42744-y, published online 02 November 2023
In the “Discussion” section of the original manuscript, the authors reported information and data related to an unpublished work (Metoikidou C. and colleagues). Considering the confidential nature of these data, it has been decided to remove the related paragraph from the “Discussion” section. The original text has been replaced with the following statement:
“In an ongoing analysis by single-cell RNA sequencing on tumors from a subset of patients from the SYNERGY trial, Metoikidou C. and colleagues observed distinct transcriptomic and TCR-clonal patterns in responders vs. non-responder patients and between treatment arms (personal communication). These analyses will shed light on the immune parameters associated with outcome to chemo-immunotherapy.”
These changes have been implemented in the PDF and HTML versions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Buisseret, L., Loirat, D., Aftimos, P. et al. Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nat Commun 14, 8223 (2023). https://doi.org/10.1038/s41467-023-44071-8
Published:
DOI: https://doi.org/10.1038/s41467-023-44071-8
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
